Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia. - Test2 - elhamkhani - TriplyDB

Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia.

Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia.

http://www.wikidata.org/entity/Q33710062

about

Analysis of hedgehog signaling in periocular sebaceous carcinoma.Role of GLI Transcription Factors in Pathogenesis and Their Potential as New Therapeutic Targets

P2860

Q48504782-BDB17AE1-3ED2-4D95-9A54-F738C7B5FF1E Q58692807-85323877-BABE-4096-ACC3-29C512FE0760

P2860

Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia.

http://www.wikidata.org/entity/Q33710062

description

2017 nî lūn-bûn

@nan

2017 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի մարտին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Combined inhibition of GLI and ...... human acute myeloid leukemia.

@ast

Combined inhibition of GLI and ...... human acute myeloid leukemia.

@en

type

label

Combined inhibition of GLI and ...... human acute myeloid leukemia.

@ast

Combined inhibition of GLI and ...... human acute myeloid leukemia.

@en

prefLabel

Combined inhibition of GLI and ...... human acute myeloid leukemia.

@ast

Combined inhibition of GLI and ...... human acute myeloid leukemia.

@en

P1433

Q33710062-BAFE4050-5F09-4277-8BCF-1D1738EEB260

P1476

Q33710062-39EB122C-9BAB-4752-A5D9-6C5934B57B59

P2093

Q33710062-01E57BA3-FAA5-4721-A0AB-8E3E000E8BEA

Q33710062-026FCBBE-A468-443A-9CF4-FE85F179561A

Q33710062-049B6963-02D9-4D86-8740-2FB91280A8F2

Q33710062-8A0486ED-BFD1-4FA1-B576-B3CC25B079FE

Q33710062-95AA38F0-B3AD-4F68-9AAA-2D73AF95DBD8

Q33710062-A4724A3C-25BF-4EA6-A8EA-513005A3AF3F

Q33710062-AE13177D-758A-4A8A-80B1-1AF1A6E60DCC

Q33710062-AEE18DF3-36AF-4017-B61A-53A91186CF66

Q33710062-B840196C-BF33-4C5F-B4CD-05125F9BDF54

Q33710062-C6BA3495-EEBF-49B9-9A3F-AEF5F26A8DCD

P2860

Q33710062-0052109D-F649-4A32-ABBC-56937E18EED2

Q33710062-05435AE1-9188-4C3E-9814-C9F06F3CE22D

Q33710062-06C24E2B-DDE9-4AA2-85DB-2ABBA7D04687

Q33710062-08054571-434C-4DA7-9349-3F77846A0F3C

Q33710062-17C8A782-CAF8-4B99-ABE1-CE0E91CEF8F1

Q33710062-185CD0F3-BE3A-4FBA-A791-472E5DE87EFB

Q33710062-1BD67269-B7D0-45CA-B39B-3D8B8EE9C05F

Q33710062-20C527DD-C2CF-4A31-9962-4B8E1A7F3ADE

Q33710062-232A5312-C553-48E6-9208-88E08DC30B3D

Q33710062-260B42BF-FDA1-44A5-8B47-2779E9397EC7

P304

Q33710062-845D857F-AB25-4CD7-836D-A6E458B6F130

P31

Q33710062-0D6484A8-7B44-448F-857F-462280AA60EE

P356

Q33710062-2681AAE0-585A-4585-8213-D4AB66A06996

P407

Q33710062-609524B9-BAC0-4E4C-9134-C666D25276DD

P433

Q33710062-D68A84C9-2C4B-441E-AF64-0C0A478EE761

P478

Q33710062-A3CD9D35-CBC8-48EB-A4B5-8E77DCD13DA1

P577

Q33710062-8A73E26E-9B9D-4E96-95BB-6AE7D0DCAE34

P698

Q33710062-BECE7EE2-8366-4B2E-8E83-1BED3866578B

P921

Q33710062-66F75CFA-C2EC-4186-99D9-E449F57DB7BA

P932

Q33710062-450FE3BF-4D33-44D5-9202-790125AB72F7

P356

ONCOTARGET.16304

P1433

P1476

Combined inhibition of GLI and ...... human acute myeloid leukemia.

@en

P2093

Carsten Bokemeyer

http://www.w3.org/2001/XMLSchema#string

Emily-Marie Latuske

http://www.w3.org/2001/XMLSchema#string

Gabi Vohwinkel

http://www.w3.org/2001/XMLSchema#string

Hauke Stamm

http://www.w3.org/2001/XMLSchema#string

Jana Muschhammer

http://www.w3.org/2001/XMLSchema#string

Jasmin Wellbrock

http://www.w3.org/2001/XMLSchema#string

Manfred Jücker

http://www.w3.org/2001/XMLSchema#string

Marianne Klokow

http://www.w3.org/2001/XMLSchema#string

Maxim Kebenko

http://www.w3.org/2001/XMLSchema#string

Walter Fiedler

http://www.w3.org/2001/XMLSchema#string

P2860

The crosstalk of mTOR/S6K1 and Hedgehog pathways

Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.

Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell

The Hedgehog and Wnt signalling pathways in cancer

Hedgehog signaling in animal development: paradigms and principles

Induction of sonic hedgehog mediators by transforming growth factor-beta: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo

Tissue repair and stem cell renewal in carcinogenesis

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.

Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia

P304

29187-29201

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.16304

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28418873

http://www.w3.org/2001/XMLSchema#string

P921

P932

5438723

http://www.w3.org/2001/XMLSchema#string